Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights from FOURIER

The FOURIER trial randomized 27,564 patients with established ASCVD and LDL-C ≥70 mg/dL on optimized statin therapy to evolocumab or placebo. This pre-specified analysis examined Lp(a) levels, the effect of evolocumab on Lp(a), and whether Lp(a) reduction independently predicted cardiovascular event reduction in 25,096 patients with available data.

Evolocumab reduced Lp(a) by approximately 27% from baseline. Baseline Lp(a) was independently associated with residual cardiovascular risk in placebo-treated patients: the highest Lp(a) quartile had a 46% higher event rate than the lowest, even after LDL-C adjustment. Patients with high baseline Lp(a) who received evolocumab derived greater absolute benefit — and the Lp(a) reduction contributed to, but did not fully explain, the clinical benefit of evolocumab.

The clinical significance of this analysis is substantial. It establishes three things. First, Lp(a) is an independent residual risk factor even in patients already on aggressive statin therapy. Second, PCSK9 inhibitors reduce Lp(a) by roughly a quarter — a pharmacological effect unavailable with statins (which do not lower Lp(a) and may slightly raise it). Third, patients with the highest Lp(a) derive disproportionate benefit from PCSK9 inhibition, suggesting that Lp(a) status should inform treatment selection.

We rate the evidence strong. A well-powered pre-specified analysis establishing Lp(a) as an independent PCSK9 inhibitor response predictor — among the most important analyses in the FOURIER dataset for lipid-lowering strategy.